Kymera Therapeutics (KYMR) statistics

Analysts' price targets and ratings, ownership, short interest, trading figures and dates for Kymera Therapeutics, as the data feed reports them.

Analysts' mean target, 23 analysts
$145.22
19.5% above the price

The 23 analysts reported by the data feed have a mean price target for Kymera Therapeutics of $145.22, 19.5% above the $121.52 price (range $116.00–$180.00). 12.57% of the float was sold short as of Oct 30, 2026. Institutions hold 116.1% of the shares and insiders 2.1%. Source: Yahoo Finance, read Nov 17, 2026.

Key facts

Analysts' mean target
$145.22+19.5% vs price
Analysts
23
Short interest
12.57%of float, Oct 30, 2026
Short ratio
9.52 days
Institutions
116.1%
Insiders
2.07%
Beta
2.03

Figures read . Source: Yahoo Finance (quoteSummary: key statistics, financial data, recommendation trend, major holders, insider purchases, calendar events). Analysts' targets and ratings, ownership and short interest are the data feed's figures and can lag the filings and exchange reports they come from. Figures, not advice.

Analysts' consensus as reported by the data feed

23 analysts covering Kymera Therapeutics, as the data feed counts them. Price targets and ratings are other people's estimates — not facts about the company, and not advice. Distances are from the latest price the feed gave with these figures, $121.52.

Analysts' price targets for Kymera Therapeutics
Mean price target$145.2219.5% above the price (+19.5%)
Median price target$144.0018.5% above the price (+18.5%)
Highest target$180.0048.1% above the price (+48.1%)
Lowest target$116.004.5% below the price (−4.5%)
Analysts with a target23

Ratings this month · 24 analysts

Strong buy 5(21%)Buy 17(71%)Hold 2(8%)
Analysts' ratings of Kymera Therapeutics this month, by rating
RatingAnalystsShare
Strong buy521%
Buy1771%
Hold28%
Sell00%
Strong sell00%

The feed averages these to 1.38 on its scale of 1 (strong buy) to 5 (strong sell), which it labels “strong buy”.

Who owns Kymera Therapeutics

Ownership of Kymera Therapeutics
Held by institutions116.1%426 institutions; percent of shares outstanding
Held by institutions, of the float118.6%
Held by insiders2.07%percent of shares outstanding
Shares outstanding85.37M
Float68.26Mshares available to trade
Insiders' net purchases, six months−1.61M10 purchases (295.53K shares), 10 sales (1.9M shares)

Percentages are of shares outstanding unless the row says float. Insiders' net purchases are shares bought minus shares sold by insiders, as the data feed totals their reported trades.

Short interest as reported by the data feed

Shares sold short and not yet covered, as of Oct 30, 2026. Short interest is counted twice a month, so this is not today's figure.

Short interest in Kymera Therapeutics
Shares short8.4Mas of Oct 30, 2026
Percent of float12.57%shares short ÷ float
Percent of shares outstanding9.84%shares short ÷ shares outstanding
Short ratio (days to cover)9.52shares short ÷ average daily volume

Kymera Therapeutics short interest from FINRA, with its history

Trading figures

Trading figures for Kymera Therapeutics
Beta2.03movement against the market; 1 moves with it
52-week high$142.92
52-week low$62.91
Average volume, 3 months837.36Kshares a day
Average volume, 10 days1.1Mshares a day

Questions and answers

What is the analysts' price target for Kymera Therapeutics (KYMR)?

As reported by the data feed, the mean price target of the 23 analysts covering Kymera Therapeutics is $145.22, 19.5% above the latest price of $121.52. The highest target is $180.00 and the lowest $116.00. Targets are analysts' estimates, not facts about the company and not advice.

How do analysts rate Kymera Therapeutics stock?

Of the 24 ratings the data feed reports for the current month, 5 are strong buy, 17 buy, 2 hold, 0 sell and 0 strong sell.

How many Kymera Therapeutics shares are sold short?

As reported by the data feed, 8.4M shares were sold short, 12.57% of the float as of Oct 30, 2026. At the average daily volume that is 9.52 days to cover. Short interest is reported twice a month; it is not today's figure.

Who owns Kymera Therapeutics stock?

As reported by the data feed, institutions hold 116.1% of the shares (426 institutions) and insiders 2.1%. There are 85.37M shares outstanding, of which 68.26M are in the float.

How much does Kymera Therapeutics stock move with the market?

Its beta, as reported by the data feed, is 2.03: a beta above 1 means the share has tended to move more than the market, below 1 less. Over the past 52 weeks it traded between $62.91 and $142.92.

Cite this page

Funkfolio, “Kymera Therapeutics (KYMR) statistics and analyst targets”, data as of 17 November 2026. https://funkfolio.com/stock/KYMR/statistics

Underlying data: Yahoo Finance.